Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the rate of pathological complete response (pCR) to the sequential
therapy of Doxil, paclitaxel, and cyclophosphamide with concurrent Avastin for patients with
locally advanced invasive (T2,T3, Nany, M0) breast carcinoma. Also, the study will evaluate
the clinical and subclinical cardiotoxic effect(s) of this regimen, assess how feasible and
safe the study is. Survival without any progression of disease will also be calculated.
A regimen of chemotherapy will be given to replicate the high rate of pCR seen with
conventional chemotherapy in patients with locally advanced breast cancer. Doxil will
substitute the normally given doxorubicin. It is expected that the low effect or minimal
effect of Doxil on cardiac function will minimize any additional risk of cardiotoxicity from
Avastin. It is expected that clinical and subclinical rates of cardiotoxicity will be very
low at the total doses to be given in this clinical trial.